Synbiotics

Synbiotics has been studied in 104 papers since 2017: 14 trials and 1 observational study in people, 1 in animals, 82 reviews; 54 in the past year. The newest paper, Nov 19, 2026: “Effects of synbiotic supplementation on serum lipids, lipoproteins and blood pressure in kidney transplant recipients with overweight or obesity: a randomised controlled trial”.

Intervention

104 papers study it56 findingsUpdated

MeSH

Research on it is growing 104% faster than aging research as a whole: 12 papers in the latest year counted

More supplements

14 new papers in 30 daysSee all 102 papers on synbiotics

At a glance

Synbiotics are linked with lower mortality in a human observational study. Independent labs report reduced inflammation, lower TNF-alpha and increased IL-10 in humans. Reviews describe lower C-reactive protein, but a human trial shows no clear effect; body-weight results also differ.

56 findings in 22 papers from 2017 to 2026, 4 of them since August 2026

Independent labs found the same change in people. 12 independent labs in 7 countries; 3 trials, none about aging.

“As seen in Table, over the 4 months, the mean body weight significantly reduced in the synbiotic group, compared to the placebo group, even after adjusting for weight baseline values and energy intakes of participants (p < 0.001).”
The promising effects of a multi-species synbiotic preparation on metabolic profile in elderly patients with type 2 diabetes and high cardiovascular risk: a randomized, triple-blind, placebo-controlled trialNutrition & diabetes2025doi:10.1038/s41387-025-00408-4

2 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 12 independent labs in 7 countries
  • 2 findings against
  • 3 trials, none about aging
  • Funders: Tabriz University of Medical Sciences and others
  • Human trial14
  • Humans1
  • Animals1
  • In silico1

11 studies gave synbiotics to people and measured what changed.

What changedDesignPeopleSource

down: Decreases total cholesteroleffect size −0.75

down: Decreases systolic blood pressureeffect size −0.74

no change: Has no effect on HDL cholesterol

Randomized trial12 weeks46 peopleKidney transplant recipients with overweight or obesityThe British journal of nutrition, Nov 19, 2026

down: Decreases fat massmedian −3.00 kg at T6, p < 0.001

no change: Has no effect on fat-free mass

Trial6 months17 peopleWomenmean age 52 ± 2.6 yearsPostmenopausal women; Midlife adults; perimenopausal women with migraine and intestinal dysbiosisPreprints.org, Sep 16, 2026

no change: Has no effect on physical function

Randomized trial12 weeks51 peoplemen65–79 yearsCommunity-dwelling men with type 2 diabetes mellitusEuropean journal of nutrition, Aug 19, 2026

down: Decreases lipopolysaccharide-binding protein

Randomized trial12 weeks48 peopleaged 22–73 yearsOverweight or obese kidney transplant recipients in the chronic post-transplant phaseRenal failure, Mar 26, 2026

down: Decreases low-density lipoprotein cholesterol

down: Decreases fasting blood sugar

down: Decreases alanine aminotransferase

Randomized trial12 weeks80 peoplePatient cohortsEuropean journal of medical research, Jan 30, 2026

What did studies of synbiotics find?

37

Studies of synbiotics measured 37 outcomes; the most studied are inflammation (4 studies), IL-10 (3) and systolic blood pressure (2).

Inflammation

downin humans4

4 studies
  1. Synbiotics decrease inflammation in overweight or obese kidney transplant recipients on a calorie-restricted diet.

    “The reduction in serum hs-CRP in the synbiotic group was statistically significant when compared to the placebo group (p = 0.02; ).”

    Human trialin overweight or obese kidney transplant recipients on a calorie-restricted diet12 weeks

    Synbiotic supplementation reduces intestinal permeability and inflammation in overweight or obese kidney transplant recipients: a randomized controlled trial

    Renal failure

  2. Synbiotics decrease inflammation in humans (p = 0.02).

    “Serum LBP (p = 0.03), hs-CRP (p = 0.02), ICAM-1 (p = 0.04), and IL-6 (p = 0.02) showed significant reductions in the synbiotic group compared to the placebo group.”

    Human trialcapsules12 weeks

    Synbiotic supplementation reduces intestinal permeability and inflammation in overweight or obese kidney transplant recipients: a randomized controlled trial

    Renal failure

  3. Synbiotics decrease inflammation in humans (combined with lifestyle modifications).

    “significant improvements in some measures of lipid profile (TC and LDL-C), FBS, liver function (ALT and AST), and liver inflammatory biomarkers (TNF-α and IL-6)”

    Human trialcombined with lifestyle modifications12 weeksn = 80

    Multi-strain synbiotic and lifestyle modifications on patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a randomized double-blinded placebo-controlled trial

    European journal of medical research

  4. Synbiotics decrease inflammation in humans (metabolic syndrome).

    “synbiotics may restore microbial balance, improve metabolic homeostasis, and attenuate inflammatory pathways.”

    Reviewmetabolic syndrome

    Effect of supplementation with synbiotics in metabolic syndrome: mechanisms and clinical implications

    Minerva gastroenterology

  5. Synbiotics decrease inflammation in humans (stress-induced inflammation).

    “Prebiotics and probiotics, which modulate the gut flora, have been shown to improve mood, reduce stress-induced inflammation, and preserve metabolic balance.”

    Reviewstress-induced inflammation

    Psychological Health and Slowing Metabolism: The Role of Pre/Probiotics in Aging

    Preprints.orgPreprint

More on Inflammation

IL-10

upin humans3

3 studies
  1. Synbiotics increase IL-10 in humans.

    “The anti-inflammatory IL-10 was significantly upregulated in both stressed and non-stressed participants.”

    Human trial12 weeksn = 32

    The Effects of Synbiotics Administration on Stress-Related Parameters in Thai Subjects-A Preliminary Study

    Foods (Basel, Switzerland)

  2. Synbiotics increase IL-10 in humans (significant only in synbiotic group versus placebo).

    “IL-10 was significantly increased only in the S-group”

    Human trialsignificant only in synbiotic group versus placebo

    Synbiotic supplementation, systemic inflammation, and symptoms of brain disorders in elders: A secondary study from a randomized clinical trial

    Nutritional neuroscience

  3. Synbiotics increase IL-10 in humans (SMD 0.30, 95% CI 0.002 to 0.59).

    “Conversely, anti-inflammatory IL-10 significantly increased (SMD: 0.30, 95% CI: 0.002 to 0.59).”

    ReviewAt least 3 weeks

    Effects of synbiotic supplementation on inflammatory and anti-inflammatory markers in adults: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials

    BioImpacts : BI

More on IL-10

Systolic blood pressure

downin humans2

2 studies
  1. Synbiotics decrease systolic blood pressure in humans (kidney transplant recipients with overweight or obesity; compared with placebo) (effect size −0.74).

    “systolic blood pressure ( P = 0·034; effect size: −0·74) in the synbiotic group compared with the placebo group.”

    Human trialkidney transplant recipients with overweight or obesity; compared with placebocapsulestwo capsules daily12 weeksn = 46

    Effects of synbiotic supplementation on serum lipids, lipoproteins and blood pressure in kidney transplant recipients with overweight or obesity: a randomised controlled trial

    The British journal of nutrition

  2. Synbiotics decrease systolic blood pressure in humans (NAFLD; compared with placebo) (Change: -16.07±3.56 mmHg; placebo: -1.55±3.01 mmHg; P=0.01 across groups).

    “combined symbiotic and alpha-tocopherol, symbiotic and alpha-tocopherol alone administration, compared with the placebo, resulted in significant decreases in SBP”

    Human trialNAFLD; compared with placebo2 × 108 CFU/g8 weeks

    Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease

    EXCLI journal

C-reactive protein

downin humans1no changein humans1

2 studies
  1. Synbiotics showed no clear effect on C-reactive protein in humans (between study groups, both groups on a low-calorie diet) (P=0.550 between study groups).

    “We did not observe any significant effects of the synbiotic supplementation in hs-CRP, and IL-1β between the study groups (P=0.550, P=0.118 respectively).”

    Human trialbetween study groups, both groups on a low-calorie diet10 weeks

    The effects of synbiotic supplementation on serum inflammatory markers and edema volume in breast cancer survivors with lymphedema

    EXCLI journal

  2. Synbiotics decrease C-reactive protein in humans (SMD -0.49, 95% CI -0.67 to -0.31).

    “Synbiotic supplementation was associated with a reduction in C-reactive protein (CRP) (SMD: -0.49, 95% CI: -0.67 to -0.31)”

    ReviewAt least 3 weeksn = 3,725

    Effects of synbiotic supplementation on inflammatory and anti-inflammatory markers in adults: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials

    BioImpacts : BI

More on C-reactive protein

Body weight

no changein humans1downin humans1

2 studies
  1. Synbiotics showed no clear effect on body weight in humans (combined with lifestyle modifications).

    “No significant changes were observed in anthropometric measures either within or between groups during the study period.”

    Human trialcombined with lifestyle modifications12 weeksn = 80

    Multi-strain synbiotic and lifestyle modifications on patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a randomized double-blinded placebo-controlled trial

    European journal of medical research

  2. Synbiotics decrease body weight in humans.

    “As seen in Table, over the 4 months, the mean body weight significantly reduced in the synbiotic group, compared to the placebo group, even after adjusting for weight baseline values and energy intakes of participants (p < 0.001).”

    Human trial4 monthsn = 96

    The promising effects of a multi-species synbiotic preparation on metabolic profile in elderly patients with type 2 diabetes and high cardiovascular risk: a randomized, triple-blind, placebo-controlled trial

    Nutrition & diabetes

More on Body weight

TNF-alpha

downin humans2

2 studies
  1. Synbiotics decrease TNF-alpha in humans (between study groups, both groups on a low-calorie diet) (P=0.039 between study groups).

    “synbiotic supplementation resulted in a significant reduction in leptin (P=0.003) and TNF-α (P=0.039) between the study groups”

    Human trialbetween study groups, both groups on a low-calorie diet10 weeks

    The effects of synbiotic supplementation on serum inflammatory markers and edema volume in breast cancer survivors with lymphedema

    EXCLI journal

  2. Synbiotics decrease TNF-alpha in humans (SMD = -0.36).

    “whereas synbiotics reduced TNF-α (SMD = -0.36).”

    Review

    Effects of probiotics, prebiotics, and synbiotics on gut microbiota in older adults: a systematic review and meta-analysis of randomized controlled trials

    Nutrition journal

More on TNF-alpha

Lipopolysaccharide-binding protein

downin humans1

1 study
  1. Synbiotics decrease lipopolysaccharide-binding protein in overweight or obese kidney transplant recipients on a calorie-restricted diet.

    “However, the reduction of serum LBP concentration was significantly higher in the synbiotic group than in the placebo group (p = 0.03; ).”

    Human trialin overweight or obese kidney transplant recipients on a calorie-restricted diet12 weeks

    Synbiotic supplementation reduces intestinal permeability and inflammation in overweight or obese kidney transplant recipients: a randomized controlled trial

    Renal failure

  2. Synbiotics decrease lipopolysaccharide-binding protein in humans (p = 0.03).

    “Serum LBP (p = 0.03), hs-CRP (p = 0.02), ICAM-1 (p = 0.04), and IL-6 (p = 0.02) showed significant reductions in the synbiotic group compared to the placebo group.”

    Human trialcapsules12 weeks

    Synbiotic supplementation reduces intestinal permeability and inflammation in overweight or obese kidney transplant recipients: a randomized controlled trial

    Renal failure

More on Lipopolysaccharide-binding protein

VCAM-1

downin humans1

1 study
  1. Synbiotics decrease VCAM-1 in humans.

    “As seen in Table, the mean serum VCAM-1 level decreased significantly in the synbiotic group, compared to the placebo group after adjusting for VCAM-1 baseline values (p < 0.001).”

    Human trial4 monthsn = 96

    The promising effects of a multi-species synbiotic preparation on metabolic profile in elderly patients with type 2 diabetes and high cardiovascular risk: a randomized, triple-blind, placebo-controlled trial

    Nutrition & diabetes

  2. Synbiotics decrease VCAM-1 in humans (type 2 diabetes and high cardiovascular risk) (-85.70 ng/L (-150.14 to -21.26)).

    “vascular cell adhesion molecule 1 (VCAM-1) [-85.70 ng/L (-150.14 to -21.26)]”

    Human trialtype 2 diabetes and high cardiovascular risk4 monthsn = 85

    The promising effects of a multi-species synbiotic preparation on metabolic profile in elderly patients with type 2 diabetes and high cardiovascular risk: a randomized, triple-blind, placebo-controlled trial

    Nutrition & diabetes

More on VCAM-1

LDL-C

downin humans1

1 study
  1. Synbiotics decrease LDL-C in humans.

    “Synbiotic supplements were better than placebo in decreasing the LDL-C after adjusting for LDL baseline values (p = 0.002).”

    Human trial4 monthsn = 96

    The promising effects of a multi-species synbiotic preparation on metabolic profile in elderly patients with type 2 diabetes and high cardiovascular risk: a randomized, triple-blind, placebo-controlled trial

    Nutrition & diabetes

  2. Synbiotics decrease LDL-C in humans (type 2 diabetes and high cardiovascular risk) (-10.83 mg/dl (-14.78 to -6.88)).

    “The mean serum Low-density-Lipoprotein (LDL-C) [-10.83 mg/dl (-14.78 to -6.88)], and total cholesterol [-11.78 mg/dl (-16.44 to -7.11)]”

    Human trialtype 2 diabetes and high cardiovascular risk4 monthsn = 85

    The promising effects of a multi-species synbiotic preparation on metabolic profile in elderly patients with type 2 diabetes and high cardiovascular risk: a randomized, triple-blind, placebo-controlled trial

    Nutrition & diabetes

More on LDL-C

Fasting plasma glucose

downin humans1

1 study
  1. Synbiotics decrease fasting plasma glucose in humans.

    “There was a significant difference between the synbiotic and placebo groups after adjusting for FPG baseline values and weight changes due to the treatment (p = 0.003).”

    Human trial4 monthsn = 96

    The promising effects of a multi-species synbiotic preparation on metabolic profile in elderly patients with type 2 diabetes and high cardiovascular risk: a randomized, triple-blind, placebo-controlled trial

    Nutrition & diabetes

  2. Synbiotics decrease fasting plasma glucose in humans (type 2 diabetes and high cardiovascular risk) (-22.83 mg/dl (-31.30 to -14.36)).

    “fasting plasma glucose (FPG) [-22.83 mg/dl (-31.30 to -14.36)], and homeostatic model assessment for insulin resistance (HOMA-IR.) [-1.31 (-1.75 to -0.86)] improved in the synbiotic group significantly”

    Human trialtype 2 diabetes and high cardiovascular risk4 monthsn = 85

    The promising effects of a multi-species synbiotic preparation on metabolic profile in elderly patients with type 2 diabetes and high cardiovascular risk: a randomized, triple-blind, placebo-controlled trial

    Nutrition & diabetes

More on Fasting plasma glucose

Lipopolysaccharide

downin humans1

1 study
  1. Synbiotics decrease lipopolysaccharide in humans (70.35 ± 11.43 to 28.57 ± 8.84 pg/mL in stressed; 66.78 ± 13.73 to 16.01 ± 3.74 pg/mL in non-stressed).

    “Synbiotics attenuated LPS level in both stressed participants (70.35 ± 11.43 to 28.57 ± 8.84 pg/mL, p < 0.001) and non-stressed participants (66.78 ± 13.73 to 16.01 ± 3.74 pg/mL, p = 0.002), whereas it promoted IgA elevation.”

    Human trial12 weeksn = 32

    The Effects of Synbiotics Administration on Stress-Related Parameters in Thai Subjects-A Preliminary Study

    Foods (Basel, Switzerland)

  2. Synbiotics decrease lipopolysaccharide in humans.

    “cortisol, and lipopolysaccharide (LPS) were reduced”

    Human trial12 weeksn = 32

    The Effects of Synbiotics Administration on Stress-Related Parameters in Thai Subjects-A Preliminary Study

    Foods (Basel, Switzerland)

More on Lipopolysaccharide

Thai Stress Test negative scale score

downin humans1

1 study
  1. Synbiotics decrease Thai Stress Test negative scale score in the stressed group (from 13.53 ± 1.20 at the baseline to 8.21 ± 1.33 at the 12th week).

    “Although there was no significant change of stress status in the stressed group, the outcome was exhibited the decreasing negative scale scores of TST from 13.53 ± 1.20 at the baseline to 8.21 ± 1.33 at the 12th week; p = 0.001.”

    Human trialin the stressed group12 weeks

    The Effects of Synbiotics Administration on Stress-Related Parameters in Thai Subjects-A Preliminary Study

    Foods (Basel, Switzerland)

  2. Synbiotics decrease Thai Stress Test negative scale score in humans (stressed participants) (p < 0.05).

    “In the stressed group, the administration of synbiotics significantly (p < 0.05) reduced the negative scale scores of TST”

    Human trialstressed participants12 weeksn = 32

    The Effects of Synbiotics Administration on Stress-Related Parameters in Thai Subjects-A Preliminary Study

    Foods (Basel, Switzerland)

More on Thai Stress Test negative scale score

HDL cholesterol

no changein humans1

1 study
  1. Synbiotics showed no clear effect on HDL cholesterol in humans (kidney transplant recipients with overweight or obesity).

    “However, there were no significant changes in serum HDL-cholesterol and Lp(a) for either group throughout the study period.”

    Human trialkidney transplant recipients with overweight or obesitycapsulesserumtwo capsules daily12 weeksn = 46

    Effects of synbiotic supplementation on serum lipids, lipoproteins and blood pressure in kidney transplant recipients with overweight or obesity: a randomised controlled trial

    The British journal of nutrition

More on HDL cholesterol

Total cholesterol

downin humans1

1 study
  1. Synbiotics decrease total cholesterol in humans (kidney transplant recipients with overweight or obesity; compared with placebo) (effect size −0.75).

    “The results indicated significant reductions in serum total cholesterol ( P = 0·022; effect size= −0·75)”

    Human trialkidney transplant recipients with overweight or obesity; compared with placebocapsulesserumtwo capsules daily12 weeksn = 46

    Effects of synbiotic supplementation on serum lipids, lipoproteins and blood pressure in kidney transplant recipients with overweight or obesity: a randomised controlled trial

    The British journal of nutrition

More on Total cholesterol

Fat-free mass

no changein humans1

1 study
  1. Synbiotics showed no clear effect on fat-free mass in humans (perimenopausal women with migraine and intestinal dysbiosis).

    “with FFM remaining broadly stable”

    Human trialperimenopausal women with migraine and intestinal dysbiosis6 monthsfemales

    Fat-Free Mass Is Associated with Migraine Disability in Perimenopausal Women: A Pre-Specified Exploratory Analysis of the MEDEA Study

    Preprints.orgPreprint

More on Fat-free mass

All 37

What is synbiotics linked with?

3

Studies link synbiotics with 3 measures: gut microbiota composition, mortality and neurodegenerative disease.

Gut microbiota composition

mixedin reviews1

1 study
  1. Synbiotics are associated with gut microbiota composition.

    “Prebiotics and probiotics have been shown to modulate the gut microbiota”

    Review

    The Link Between Exercise and Diminishing Body Metabolism: How Pre/Probiotics Help Maintain a Healthy Aging Process

    Preprints.orgPreprint

Mortality

downin humans1

1 study
  1. Synbiotics are linked with a lower risk of mortality in humans.

    “nondietary prebiotic and probiotic supplement intake was also associated with a reduced risk of mortality in an older US population”

    Humans

    Association of dietary live microbe intake with all-cause and cardiovascular mortality in an older population: Evidence from NHANES 2003-2018

    Archives of gerontology and geriatrics

Neurodegenerative disease

downin reviews1

1 study
  1. Synbiotics lower the risk of neurodegenerative disease.

    “the risk of neurodegenerative diseases can be reduced by using probiotics, or preferably by combining probiotics and prebiotics, also known as synbiotics”

    Review

    Modifying progression of aging and reducing the risk of neurodegenerative diseases by probiotics and synbiotics

    Frontiers in bioscience (Elite edition)

More on Neurodegenerative disease

Has synbiotics been tested in people?

0 of 3 about aging

Yes: 14 trials and 1 observational study in people have been published, and 3 trials are registered.

In trials

Who is developing synbiotics?

1 company: Leeuwenhoek Laboratories.

Companies
  • Leeuwenhoek LaboratoriesPhase 2obesity

Trial sponsors

Funding

2 grants since 2024

Japan Society for the Promotion of Science¥4.6MInnovative UK£186K

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 4Jan 2026: 5Feb 2026: 4Mar 2026: 8Apr 2026: 1May 2026: 2Jun 2026: 2Jul 2026: 1Aug 2026: 4Sep 2026: 7Oct 2026: 11Nov 2026: 251 papers in 12 months

See all 102 papers on synbiotics